Detection of CRISPR-mediated genome modifications through altered methylation patterns of CpG islands. by Farris, M Heath et al.
The Jackson Laboratory 
The Mouseion at the JAXlibrary 
Faculty Research 2020 Faculty Research 
12-2-2020 
Detection of CRISPR-mediated genome modifications through 
altered methylation patterns of CpG islands. 
M Heath Farris 
Pamela A Texter 
Agustin A Mora 
Michael V. Wiles 
Ellen F Mac Garrigle 
See next page for additional authors 
Follow this and additional works at: https://mouseion.jax.org/stfb2020 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Authors 
M Heath Farris, Pamela A Texter, Agustin A Mora, Michael V. Wiles, Ellen F Mac Garrigle, Sybil A Klaus, and 
Kristine Rosfjord 
METHODOLOGY ARTICLE Open Access
Detection of CRISPR-mediated genome
modifications through altered methylation
patterns of CpG islands
M. Heath Farris1* , Pamela A. Texter1, Agustin A. Mora1, Michael V. Wiles2, Ellen F. Mac Garrigle1, Sybil A. Klaus1
and Kristine Rosfjord1
Abstract
Background: The development and application of CRISPR technologies for the modification of the genome are
rapidly expanding. Advances in the field describe new CRISPR components that are strategically engineered to
improve the precision and reliability of CRISPR editing within the genome sequence. Genome modification using
induced genome breaks that are targeted and mediated by CRISPR components leverage cellular mechanisms for
repair like homology directed repair (HDR) to incorporate genomic edits with increased precision.
Results: In this report, we describe the gain of methylation at typically hypomethylated CpG island (CGI) locations
affected by the CRISPR-mediated incorporation of donor DNA using HDR mechanisms. With characterization of CpG
methylation patterns using whole genome bisulfite sequencing, these CGI methylation disruptions trace the
insertion of the donor DNA during the genomic edit. These insertions mediated by homology-directed
recombination disrupt the generational methylation pattern stability of the edited CGI within the cells and their
cellular lineage within the animal strain, persisting across generations. Our approach describes a statistically based
workflow for indicating locations of modified CGIs and provides a mechanism for evaluating the directed
modification of the methylome of the affected CGI at the CpG-level.
Conclusions: With advances in genome modification technology comes the need to detect the level and
persistence of methylation change that modifications to the genomic sequence impose upon the collaterally
edited methylome. Any modification of the methylome of somatic or germline cells could have implications for
gene regulation mechanisms governed by the methylation patterns of CGI regions in the application of therapeutic
edits of more sensitively regulated genomic regions. The method described here locates the directed modification
of the mouse epigenome that persists over generations. While this observance would require supporting molecular
observations such as direct sequence changes or gene expression changes, the observation of epigenetic
modification provides an indicator that intentionally directed genomic edits can lead to collateral, unintentional
epigenomic changes post modification with generational persistence.
Keywords: CRISPR genome editing, Homology-directed repair, Non-homologous end-joining, Epigenetic
modification, CpG island, Methylation variance, Statistical variance detection
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Background
The emergence of rapid genome editing methodologies
facilitated by CRISPR/Cas9 [1] and similar technologies
has opened the ability to generated stable and precise
edits within animal models [2], accelerating the rate of
disease research and creating a shorter path toward dis-
ease treatments, therapeutic applications, and agricul-
tural improvements. Further, these technologies are
poised to be used in human therapeutic applications. In
regard to mice, CRISPR/Cas9-mediated edits are applied
at the zygote stages introducing various genomic muta-
tions [3, 4], resulting in the development of numerous
mouse models. Tissue- and cell-targeted applications
like somatic gene therapy can also deliver genetic modi-
fication components to the respective targets via mo-
lecular and physical carriers, including liposomes [5–7],
adeno-associated virus [8–10], lentivirus [11], and elec-
troporation [12]. These genome modification approaches
have their respective challenges and limitations; how-
ever, these and other chemical and physical transfection
methodologies have successfully generated representa-
tive mouse models of human disease, using CRISPR
components. Using similar approaches, many other spe-
cies, including humans [13], have been genetically modi-
fied by CRISPR and CRISPR-like systems.
At the application of CRISPR and similar genome edit-
ing technologies, the genome is typically edited by intro-
ducing a DNA break at the target site, leading to non-
homologous end joining (NHEJ) and resulting in indels.
When donor DNA is present, it can be incorporated
seamlessly into the break mainly by homology-directed
repair (HDR). With the rise and expansion of these tech-
nologies, the rate and precision of the complete intro-
duction of genomic modifications are increasing, as are
the diversity of species that can be edited by them. The
incorporation of specific edits into the genome using
CRISPR is mediated by the insertion of genomically
homologous sequences flanking a non-homologous in-
sertion sequence through HDR [3, 14, 15], by blunt-end
insertions and insertion/deletion (indel) mutations
through NHEJ repair mechanisms [3], or by fusions of
deactivated Cas9 with effector molecules resulting in
point modifications by base editors [16] and reverse
transcription-mediated sequence insertion by prime edi-
tors [17]. Each method provides its advantages and dis-
advantages; however, HDR methods have to-date proven
most versatile and efficient for precise introduction of
larger insertions, while NHEJ, which is slightly serendip-
itous in its outcome, is used extensively as a gene dis-
ruption tool.
In general, the genomes of vertebrates are depleted of
CpG dinucleotides; however, discrete regions of high G/
C content exist across the genome, containing a high
frequency of CpG dinucleotides. These clusters of CpG-
rich regions are known as CpG islands (CGIs) [18].
Within the mammalian system, CpG locations are avail-
able for targeted methylation by the cellular machinery,
and the genomic methylation patterns established within
CGIs are reset and reestablished during early embryo-
genesis [19, 20]. CGIs are typically located in gene pro-
moter regions, gene enhancer regions, or within genes
themselves and are thought to play an essential role in
gene expression regulatory function [21]. DNA methyl-
transferases, DNMT3A and DNMT3B in combination
with DNMT3L, establish the initial DNA methylation
pattern at CpG locations. The pattern is maintained by
DNMT1 and associated proteins through cell divisions
and during the life of the cell [22]. De novo methylation
during early development regulates the expression of de-
velopmental stage-critical genes and is facilitated by
DNMT3a and DNMT3b [23]. Although influences like
environmental exposures and tissue inflammation can
affect the methylome pattern as an animal ages [24],
CGIs with dense occurrences of CpG bases are usually
maintained in a hypomethylated state in the vertebrate
genome, while across the majority of the genome, occur-
rences of CpG are less frequent and tend to be in a
methylated state [22]. Commonly, CGIs are maintained
in an unmethylated state and play a role in the control
of gene expression. Induced changes to this preserved
methylation pattern within the epigenome can be af-
fected by environmental factors and can have transge-
nerational effects [25]. Directed reprogramming of the
epigenome can replace the epigenetic signatures ac-
quired during development, or imposed by the environ-
ment [26]. Further, it has been shown that
reprogramming of the cell epigenome using technologies
like CRISPR has utility in directing the epigenetic repro-
gramming of cell fate and function [27–29]. These di-
rected epigenetic changes are thought to be able to
persist across generations with progeny displaying the
modifications implemented in the parental strains [26];
however, many of the fundamental mechanisms of con-
trolling CpG methylation and their impacts are not fully
understood. As previously reported, modifications within
the epigenome can be transmitted from parent to off-
spring and have been shown to be maintained over mul-
tiple generations [30]. These changes in the methylome
pattern of the genome can induce unexpected changes
in the regulation of cellular pathways and characteristics.
Through the regulation of CGI methylation patterns, the
cell controls or influences important processes, including
cellular differentiation, X chromosome inactivation, gen-
omic imprinting, skeletal muscle regeneration, trans-
generational influences, and aging processes [30]. An
unintended deregulation of regulatory elements in these
processes can have unpredictable consequences for the
cell and hence the organism [26, 31].
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In this study, we highlight perturbations of the epige-
nome induced by the incorporation of donor DNA dur-
ing CRISPR genome editing. The result of this sequence
replacement or insertion is an alteration of the methyla-
tion patterns of CGIs within the region of the genome
edit. This methylome change is linked to the footprint of
the inserted donor DNA and is inheritable across gener-
ations. CRISPR edits leveraging HDR mechanisms and
donor homology arms that are localized around CGIs
modify the methylation patterns of these CGIs, resulting
in increased methylation of the CGIs within the region.
These methylation changes within the CGIs are stable
and persist across generations. These methylome pertur-
bances were not observed in indel edits using NHEJ,
where resulting CGI methylation patterns remained un-
modified and consistent with the base unedited state of
CGI methylation in the same genetic background.
These observations are impactful for the implementa-
tion of genome edits and the development of new tools to
study CRISPR/Cas-mediated edits and CGI regulation
mechanisms. Further, modifications to potential regula-
tory elements have implications for the application of
these type genomic edits for gene therapies. Influencing
the gene expression regulatory functions of CGI methyla-
tion patterns, introduction of exogenous donor DNA that
could inadvertently methylate neighboring CGIs could
affect gene expression regulation of the modified gene or
surrounding genes. The ability to observe and direct
changes in CGI methylation patterns using CRISPR/Cas9
components also provides the opportunity for molecular
tool development. The observation of these CGI methyla-
tion changes represents one mechanism to detect applica-
tions of CRISPR technology to induce site-directed edits,
leaving genomic scars that echo through generations or-
thogonal to naturally occurring methylation patterns. Fur-
ther, leveraging the multiplexing abilities of CRISPR
technology, modification of one or many CGIs in this
manner provides a tool for tracking the functional influ-
ence of CGI disruptions within an animal and across gen-
erations in either a tissue-specific or systemic manner.
Here we describe a statistical methodology for the de-
tection of CGI methylation variance as a result of CRIS
PR-mediated genomic editing and HDR donor DNA
substitution. We find unexpected transgenerational lo-
calized methylation changes upon the addition of non-
native donor DNA to the mouse genome. These changes
could lead to unintentional changes in gene expression
and requires deeper research to understand the local
methylation modifications and the unintended influences
they may have in human and agricultural applications.
Further, these methylation perturbances provide a mo-
lecular marker for the characterization of genome edits




The methylomes of CRISPR-edited mice were evaluated
using whole genome bisulfite sequencing to determine
the modifications induced within the methylome by the
CRISPR editing process. Three edited strains and their
controls, described in Table 1, were evaluated. The epi-
genome modifications observed within the mouse strains
were secondarily introduced into the genomes by
homology-directed repair CRISPR edits. Findings de-
scribed within in the methodology here indicate an in-
crease in methylation observations within the regions of
the adopted homology arms.
The effects of homology-directed repair were evalu-
ated using two CRISPR-edited strains (HDR1 and
HDR2) obtained from The Jackson Laboratory. HDR1
(028551; C57B1/6 J-Gt(ROSA)26Sorem1(CAG-ca-
s9*,-EGFP)Rsky/J) (Fig. 1a) contained a CRISPR-mediated
homology-directed repair insertion using the pRosa-
Cas9 targeting vector with an 11-kb insert flanked by
Rosa26 locus homology regions, extending 1 kb up-
stream and 4 kb downstream from the XbaI site within
exon 1. The insert contained a codon-optimized Cas9
gene linked to an IRES-GFP. HDR2 (028543; C57BL/
6NJ-Rxfp3em2J/J) (Fig. 1b) contained a CRISPR-mediated
homology-directed repair insertion of a 2005-bp donor
DNA, containing eGFP with a poly-A signal in an
inverted orientation at the start codon of the RXfp3
locus. The original insertion vector had homology arms
of 1 kb, flanking the insertion sequence. The effects of
non-homologous end-joining repair were evaluated
using an edited strain (NHEJ1) from The Jackson La-
boratory. NHEJ1 (028573; C57BL/6 J-Gt(ROSA)26Sor-
em2Mvw/Mvw) (Fig. 1c) contained a CRISPR-mediated
non-homologous end-joining repair insertion of a 48-bp
duplex DNA oligo with no homology arms into the
Rosa26 locus. During endogenous DNA repair, a seren-
dipitous indel of − 3 bp and + 6 bp occurred. Control
strains included wild-type parental strains Control 1
(005304; C57Bl/6NJ) and Control 2 (000664; C57Bl/6 J).
Whole genome bisulfite sequencing for a genome-wide
evaluation of CpG and CGI methylation patterns
To determine differential methylation of CpG islands
across the genomes of the evaluated animals, we se-
quenced the genome-wide methylation patterns of CpGs
using whole genome bisulfite sequencing (WGBS). The
WGBS called methylation levels at CpG dinucleotide lo-
cations with high coverage (≥ 5 calls) for each animal.
The resulting sequenced methylomes were sequenced at
a high depth of coverage across the genome, allowing all
CpG site evaluations to contain a minimum of five calls
(Fig. 2). The epigenomes of HDR1 and HDR2 were se-
quenced at an average of 13× CpG coverage with a total
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Table 1 Mouse strains
Abbreviated Name JAX # Genomic Modification Details Mouse Strain
Control 1 005304 Wild-type parental strain C57Bl/6NJ
Control 2 000664 Wild-type parental strain C57Bl/6 J
HDR1 028551 CRISPR-mediated HDR insertion using the pRosa-Cas9 targeting
vector with an 11-kb insert flanked by Rosa26 locus homology
regions, extending 1 kb upstream and 4 kb downstream from
the XbaI site within exon 1. The insert contained a codon-
optimized Cas9 gene linked to an IRES-GFP.
C57B1/6 J-Gt(ROSA)26Sorem1(CAG-cas9*,-EGFP)Rsky/J
HDR2 028543 CRISPR-mediated HDR insertion of a 2005-bp donor DNA
containing eGFP with a poly A signal in an inverted orientation
at the start codon of the Rxfp3 locus. The original insertion vector
had homology arms of 1 kb, flanking the insertion sequence.
C57BL/6NJ-Rxfp3em2J/J
NHEJ1 028573 CRISPR-mediated NHEJ insertion of a 48 base pair duplex DNA
oligo with no homology arms into the Rosa26 locus. During
endogenous DNA repair, a serendipitous indel of −3 bp and +
6 bp occurred.
C57BL/6 J-Gt(ROSA)26Sorem2Mvw/Mvw
Fig. 1 Mouse strain edit sites. The methylation patterns of three CRISPR-edited animal strains were evaluated in this study, describe in detail in
Table 1. Strain HDR1 (a) contains an 11-kb insert and was recombinantly inserted into the Rxfp3 locus of the mouse genome using a 1-kb
upstream homology arm (UHA) and a 4-kb downstream homology arm (DHA). The protospacer adjacent motif (PAM) site was located at
Chr15:11,037,280. Strain HDR2 (b) contains a 2005-bp insert and was recombinantly inserted into the Rosa26 locus of the mouse genome using a
1-kb UHA and a 1-kb DHA. The PAM site was located at Chr6:113,076,025. Strain NHEJ1 (c) contains a 48-bp duplex DNA oligonucleotide
fragment incorporated into the Rosa26 locus by non-homologous end-joining. The PAM site was located at Chr6:113,076,025. For each figure, the
yellow bar indicates the CGI location
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of 758,846,055 read pairs and at an average of 11× CpG
coverage with a total of 798,607,892 read pairs, respect-
ively. NHEJ1 was sequenced at an average of 8× CpG
coverage with a total of 665,977,690 read pairs. The epi-
genomes of Control 1 and Control 2 were sequenced at
an average of 13× CpG coverage with a total of 894,080,
435 read pairs and at an average of 10× CpG coverage
with a total of 883,336,536 read pairs, respectively. Each
animal epigenome had a bisulfite conversion rate of
99%.
An algorithm was developed base on CGI parameters
defined by Gardiner-Garden and Frommer [18]. The al-
gorithm called 90,953 enriched CpG regions that were
termed CGIs within this study across the mouse gen-
ome, having a genome-wide average CGI length of
449.50 base pairs, an average CpG site content of 28.13,
and an average CG composition of 55.75%. The identi-
fied CpG sites within the CGI ranges in each autosomal
chromosome were used in statistical evaluations for
methylation variance (S1 Table).
The comparison of the average depth of CpG location
bisulfite sequencing (BS-Seq) calls for the genome and
the respective CRISPR-edited CGI range for each experi-
mental animal indicates a CpG depth of coverage in the
CGIs that is greater than the average across the genome
with an approximate 20% increase in calls at a depth of
five or more, lending support to the confidence of the
methylation observations at the CpG locations of the
CGIs (Fig. 3). The CpG locations called in the edited
CGIs were sequenced at a depth of five calls or more for
95.48% (211 of 221) of CpG locations in HDR1 Animal,
90.35% (309 of 342) of CpG locations in HDR2 Animal,
and 59.83% (70 of 117) of CpG locations in NHEJ1 Ani-
mal. Further, calls deeper than 10 calls for CpG location
were 83.26% (184 of 221) for HDR1 Animal, 45.61%
(156 of 342) for HDR2 Animal, and 6.84% (8 of 117) for
NHEJ1 Animal.
Statistical selection of CGIs with modified methylation
patterns
The statistical filters (Fig. 4) were empirically selected
and applied to the epigenetic profiles of CGIs across the
mouse genome to identify CGIs with statistically signifi-
cant positive change from the control animal (Case 1).
Correcting for the large number of evaluations made
across the total of the CGIs within each animal, the p-
values for each CGI range within the given animal com-
parison were calculated with a Bonferroni correction,
where α equals 0.05 divided by the total number of CGI
comparisons. Only a small portion of CGIs in each ani-
mal displayed significant epigenetic change from the
CGIs of the Control 1 Animal (Table 2) with each ex-
perimental comparison closely matching the results of
control comparisons. HDR1 Animal displayed 0.052%
CGI methylation change (37 of 71,120); HDR2 Animal




Fig. 2 Genome-wide sequence depth of CpG locations. WGBS was used to evaluate CpG methylation profiles within the genome of each edited
and control animal. The distribution of the number of CpG calls observed is shown for HDR1 Animal (a) with 10,835,815 CpG locations with ≥5
calls, HDR2 Animal (b) with 10,109,462 CpG locations with ≥5 calls, NHEJ1 Animal (c) with 6,382,801 CpG locations with ≥5 calls, Control 1 Animal
(d) with 11,948,365 CpG locations with ≥5 calls, and Control 2 Animal (e) with 8,754,364 CpG locations with ≥5 calls. The numbers of CpG
locations are reported in millions (M)
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334); NHEJ1 Animal displayed 0.018% CGI methylation
change (11 of 60,450); and Control 2 Animal displayed
0.044% CGI methylation change (29 of 66,545). These
similar p-value results across all animals with minimal
outlying CGIs indicate reproducible comparisons of the
large number of CGI observations, allowing enrichment
for the targeted change of the edited CGI methylome.
The surviving CGIs were reduced further through the
application of an observed biological noise filter. This fil-
ter was applied to account for minor methylation
changes that could be part of normal cellular processes
or introduced experimental biases. The surviving CGIs
were enriched for those displaying methylation changes
beyond the determined 20% threshold for change. HDR1
Animal displayed 0.027% surviving CGIs (19 of 71,120);
HDR2 Animal displayed 0.013% surviving CGIs (9 of 69,
334); NHEJ1 Animal displayed 0.008% surviving CGIs (5
of 60,450); and Control 2 Animal displayed 0.017% sur-
viving CGIs (11 of 66,545). The sites edited using donor
DNA and homology-directed repair mechanisms for
genomic incorporation (HDR1 Animal and HDR2 Ani-
mal) each displayed significant methylation changes that
placed them in the Case1 observations. The edit site of
NHEJ1 Animal did not show significant change,
highlighting the CGI sequence was not substituted for
donor DNA during the NHEJ mutation process.
CRISPR edits mediated by HDR display methylation
profiles at CGIs with distinctive increases in methylation
Closer observation of the methylome at the edited CGI
locations for the edited animals as compared to the con-
trol demonstrates the significant deviation in the methy-
lation patterns for the HDR modified CGIs. Using
locations with a minimum of five calls for each CpG,
Fig. 5a shows the complete modification of the edited
CGI (Chr15:11,035,894–11,038,084) in the experimental
animal (blue squares) beyond the anticipated 20% bio-
logical noise seen in the Control 1 Animal (red dia-
monds). The incorporation of the donor DNA homology
arms replaced the entire CGI genomic range (gold bar)
on each side of the CRISPR-targeted PAM site (dashed
line). Expanding beyond the genomic region influenced
by the homology arms of the donor DNA, Fig. 5b shows
the profile of methylation difference flanking the affected
CGI by 7000 bp upstream and downstream. These re-
sults demonstrate the increase in methylation at the edit
site as compared to the flanking genomic regions. The
observed methylation pattern for the CGI of the CRIS
PR-edited HDR1 and the Control 1 are illustrated in Fig.
5c and d, respectively. The edited CpG sites of HDR1
have elevated methylation percentages as compared to
that of Control 1.
Figure 6a illustrates the effects of the partial modifica-
tion of an edited CGI (Chr6:113,076,186–113,077,861;
gold bar). In this edit, the CRISPR-targeted PAM site
(dashed line) is located upstream of the affected CGI.
During the HDR, only the downstream homology arm
was incorporated into the affected CGI range, stretching
approximately half the length of the CGI (blue back-
ground shading). The resulting methylation pattern per-
turbation is observed in this region of the CGI only. The
downstream portion of the CGI methylome (unshaded
background) remains unmodified from that of the con-
trol animal. Figure 6b shows the methylation difference
in the genomic regions flanking the edited CGI. In-
creases of methylation are concentrated at the site of
homology arm interaction with the genome. The methy-
lation percentage observed for CRISPR-edited HDR2
(Fig. 6c) and Control 1 (Fig. 6d) demonstrate the ele-




Fig. 3 Genomic and CRISPR-edited CGI methylation depth of call
percentage. The percent of CpG calls within the respective CRISPR-
edited sites for the modified animals exceeds that observed within
the genome. For each call depth, the percentage of CpG calls are
plotted for the CRISPR-edited CGI (light blue) as related to the
genome (dark blue) for HDR1 Animal (a), HDR2 Animal (b), and
NHEJ1 Animal (c)
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border of methylation inflection at the interaction site of
the terminus of the downstream homology arm.
In contrast, the edited CGI using NHEJ repair to insert
donor DNA retains a methylation pattern that is very
similar to the Control 1 Animal, demonstrating that the
lack of replacement of the edited CGI (Chr6:113,076,
186–113,077,861; gold bar) with exogenous insert hom-
ology arms leave the CGI methylation pattern unaffected
(Fig. 7a). The NHEJ repaired CGI region is similar to
that of the Control 1 Animal, supporting the CGI falling
into the Case 4 category of CGIs in the statistical work-
flow (Table 2). Similarity between NHEJ1 and Control 1
was seen at an expanded view of the genomic region that
included 7000 bp upstream and downstream of the CGI
(Fig. 7b). The comparison of observed methylation per-
centage for NHEJ1 (Fig. 7c) and Control 1 (Fig. 7d)
showed minimal difference. These observations were
reproduced in comparisons of the edited CGIs of modi-
fied animals to the unedited CGIs of Control 2 Animal.
CGIs with statistically relevant methylation changes
CGIs containing statistically significant change from that
of the control animal and containing changes beyond
those considered biological noise were categorized as
Case 1 CGIs within the statistical workflow. Case 1 data
presented within tables are a result of comparisons be-
tween CRSPR-edited or unedited animals to Control 1
Fig. 4 Statistical filter process. The stepwise process for ranking and categorizing the CpG methylation patterns of genomic CGIs permitted the
ranking of CGI changes between edited and control animal CGIs. Significantly changed CGIs followed a path (yellow bars) toward Case 1 based
on significant p-value changes with Bonferroni correction and filtered beyond biological epigenetic noise
Table 2 Statistical and epigenetic noise filtering of experimental and control CGI methylome comparisons
The table summarizes the results of evaluating Animals HDR1, HDR2, NHEJ1, and Control 2 against Animal Control 1 using the methodology for identifying
significant changes in methylation patterns for CGIs defined in Fig. 4. *Note: The α level of 0.05 was adjusted using the Bonferroni method for each comparison;
the adjusted α = 0.05/Total CGIs. Each animal was compared against Control 1 Animal. The blue highlight indicates the Case containing the CRISPR-edited CGI for
the respective animal





Fig. 5 (See legend on next page.)
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Animal; for all evaluations, similar results were observed
in comparisons to Control 2.
Organized in smallest to largest order of p-value, the
CRISPR-edit sites using HDR in the HDR1 Animal
(3.852E-48) and the HDR2 Animal (5.384E-23) rank as
the most significantly methylated CGIs within the ge-
nomes of the experimental animals as compared to the
Control 1 Animal (Tables 3 and 4; Fig. 8a and b).
The distribution counts of the degree of CpG methyla-
tion changes within the Case 1 CGIs demonstrates an in-
crease of methylation toward complete methylation
change at modified CpG locations, after greater than ten
generations of progeny inheritance. These data highlight
the generational persistence of the epigenetic changes at
the edit sites within the progeny. The degree of methyla-
tion distribution is skewed toward the higher percentage
of increased methylation in the HDR1 Animal at the re-
gion of the edit due to complete CGI methylome modifi-
cation; while, the degree of methylation distribution is
skewed toward the higher percentage of increased methy-
lation in the HDR2 Animal, it is to a lesser degree than
the HDR1 Animal due to the incompletely modified CGI.
The genetically-edited CGI of the NHEJ1 Animal using
NHEJ repair to introduce an indel did not rank within the
most significant Case 1 CGIs for the animal (Table 5), in-
stead the edited CGI ranking within the Case 4 category
of the comparisons. The Case 1 CGIs of the NHEJ1 Ani-
mal were similar in their measure (Fig. 8c). Supplemental
Figures A and B illustrate the profiles of the top two Case
1 CGIs for the NHEJ1 Animal, indicating a non-
uniformed distribution of methylation increase unlike the
more uniformed increase displayed in the HDR edited
sites (Figs. 5 and 6).
Evaluating the Case1 results of Control 2 compared to
Control 1, the top ranked CGI (Chr11:6,006,144–6,007,
748) has a skewed distribution as in the HDR1 Animal
completely edited CGI. Further, the comparison of the
CGI methylation changes between Control 1 and Con-
trol 2 (Table 6) highlights a significantly methylated CGI
(Chr4:134,159,558–134,164,691) with similar p-values to
those observed in the partially edited CGI of the HDR2
Animal (Tables 4 and 5; Fig. 8b and d), reflecting not
only the common origins of the strains and also the
more than 250 generations of reproductive separation.
One significant difference between the significantly
methylated CGIs of the control comparisons compared
to those of the homology-directed repair edited animal
is the consistency of the CpG methylation across the
CGI. When visualized, the methylation patterns of the
CGIs between Control 1 and Control 2 (Table 6) are in-
consistent with CpG methylation calls rising and falling
irregularly across the CGIs. In contrast, the methylation
patterns of the edited sites display a uniformed increase
of methylation across the range of the incorporated
homology arm (Figs. 5 and 6).
These findings indicate that the cellular fluctuation of
the methylome due to varying biological processes of
time between the compared animals produce statistically
significant methylation changes within CGIs between
the animals, reinforcing the need to understand add-
itional confirmatory information about the top ranking
Case 1 CGIs to conclusively identify an HDR-edited
CGI. Accompanying information could include large and
small rearrangements, including insertion, deletion, or
altered base pairs [32].
While the HDR modified CGIs were identified as
containing statistically changed methylation patterns
as anticipated, both the NHEJ and control compari-
sons identified statistically changed methylation pat-
terns as well. These observations highlight the need
to understand where edits have been directed through
other indicators such as direct sequencing to confirm
an HDR-directed genome modification through
methylome evaluations. Using perturbations of CGI
methylation patterns as indicators of genomic inser-
tions allows for a measurable factor for indicating a
genetic modification, including CRISPR-mediated
HDR genomic edits.
(See figure on previous page.)
Fig. 5 Methylomic difference of a completely edited CpG island within the genome of the HDR1 Animal using homology-directed repair in a
CRISPR-mediated edit. Homology arms of a synthetic DNA fragment (region shaded in blue) in a homology-directed repair of a CRISPR-mediated
genomic cut spanned a CpG island (CGI; Chr15:11,035,894–11,038,084; yellow bar) within the genome of HDR1 Animal, resulting in a destabilized
methylation pattern (blue squares) as compared to the Control 1 Animal methylation patterns at the same location (red diamonds). Figure 4a
illustrates the localized methylation variance introduced at the CGI, while Fig. 4b illustrates the comparison of the modified region to flanking
endogenous genomic regions by displaying the variance of methylation patterns for 7000 bp upstream and downstream of the CGI. The
methylation patterns of regions not influenced by the incorporation of donor DNA during the CRISPR edit displayed a methylation pattern similar
to the control. The gray band indicates considered biological epigenetic variance (+/− 20% change). The dashed line indicates the protospacer
adjacent motif (PAM) location of the targeted CRISPR cut site. Synthetic homology arms corresponded to genomic sequence 1000 bp upstream
and downstream of the PAM site. The comparison of the percent methylation observed at the localized CGI region for the CRISPR-edited animal
(Fig. 4c) and the unedited control animal (Fig. 4d) demonstrate the introduced methylation variance as a result of the introduction of the donor
DNA. Blue squares (■) indicate the percent differences in CpG methylation for HDR1 Animal from Control 2 Animal at given chromosome
locations. Red diamonds (♦) indicate the percent differences in CpG methylation for Control 1 Animal from Control 2 Animal at given
chromosome locations





Fig. 6 (See legend on next page.)
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Discussion
The application of CRISPR approaches for the modifica-
tion of the genome offers a level of control over genomic
editing processes that can cure diseases, revive ecosys-
tems, and enhance agricultural crops and livestock. Ad-
vances in these technologies are changing the
approaches and strategies in molecular biology to modify
and regulate genomic information, generating genomic
modifications with targeted precision and specificity at
an unprecedented pace. Two commonly utilized mecha-
nisms for introducing genome modifications at CRISPR
cut sites are non-homologous end-joining (NHEJ) and
homology-directed repair (HDR). NHEJ is commonly
used to create indels leading to gene frameshifts or loss
of coding regions and inactivation of a targeted gene [3]
and can also be used to insert donor DNA in the gen-
ome [33]. In practice, this approach is less precise,
resulting in indels and is prone to serendipitous out-
comes including hypomorphs. With HDR, the cell uti-
lizes added donor DNA as a repair templated for
insertion and genomic modification, relying on genomi-
cally homologous flanking regions in the donor sequence
and the endogenous DNA repair mechanisms of the cell
to incorporate it into the genome [3, 14, 15]. The
addition of directed genomic modification by HDR, me-
diated via CRISPR, allows for the precise incorporation
of any number of genomic modifications from single
point mutations to whole gene insertions to chromo-
somal rearrangements. The findings of this study high-
light the utility of using methylome perturbances
induced by the insertion of donor DNA sequence in
HDR mechanisms as an indicator of a directed genomic
edit. With the expanding advantages of CRISPR tech-
nologies for molecular modification and observation, un-
derstanding the limiting or confounding factors of the
technology is becoming increasingly important, espe-
cially in relation to the required fidelity of gene therapy
applications. In parallel, the drive for therapeutic success
that can in application affect the germline of a given
organism also requires the development of methods for
detecting and tracking induced changes within the
genome.
Within the mammalian genome, CpG islands (CGIs)
are regions of dense clusters of CpG dinucleotides that
are stably maintained typically in a hypomethylated state
[34]. Frequently located within promoter, enhancer, or
gene regions, CGIs play an important regulatory role for
controlling expression levels of genes and gene variants
within the genome. Throughout the life of the animal,
the spatial and temporal modifications of CGI methyla-
tion patterns across the genome are critical for tissue-
specific differentiation and development [21]. The cellu-
lar regulatory maintenance of CGI methylation patterns
in an unmethylated state provides opportunity to assess
induced perturbances of the anticipated methylation pat-
tern by HDR, appearing as epigenetic scars on the gen-
ome. Within this study, these CpG-rich segments of the
mouse genome were identified using an computa-
tional search algorithm governed by the parameters of
the definition of a CGI as reported by Gardiner-
Garden and Frommer [18]. Using the algorithm, we
identified 90,953 regions across the mouse genome
with elevated CpG content (S1 Table) that we termed
as CGIs. This observation is higher than other studies
that have reported CGI observations in the mouse
genome ranging in counts of 15,500 [35], 20,500 [36],
and 37,000 [37] to name a few. Often these studies
remove duplicate genome regions to adjust counts of
these CpG-rich locations. Our definition focused on
an inclusive algorithm with more wholistic parameters
as to not exclude any regions that may fall within the
definition of a CGI but may not serve a regulatory
function within the genome or may be found in du-
plicate within the genome. Therefore, our definition
serves less as a method of characterizing a functional
role for the identified CGIs rather than as indicators
of conserved methylation patterns located within the
genome.
(See figure on previous page.)
Fig. 6 Methylomic difference of a partially edited CpG island within the genome of the HDR2 Animal using homology-directed repair in a CRIS
PR-mediated edit. The downstream homology arm of a synthetic DNA fragment (region shaded in blue) in a homology-directed repair of a CRIS
PR-mediated genomic cut spanned a portion of a CpG island (CGI; Chr6:113,076,186–113,077,861; yellow bar) within the genome of the HDR2
Animal, resulting in a destabilized methylation pattern (blue squares) as compared to the Control 1 Animal methylation patterns at the same
location (red diamonds). The regions with methylation patterns modified by the incorporation of homology arms within the CGI and upstream of
the CGI are shaded in a light blue background. While Fig. 5a illustrates the localized methylation variance introduced at the CGI, Fig. 5b illustrates
the comparison of the modified region to flanking endogenous genomic regions by displaying the variance of methylation patterns for 7000 bp
upstream and downstream of the CGI. The methylation patterns of the unmodified downstream portion of the CGI (unshaded) for the edited CGI
as well as the flanking regions of endogenous genome displayed a methylation pattern similar to the control. The gray band indicates
considered biological epigenetic variance (+/− 20% change). The dashed line indicates the protospacer adjacent motif (PAM) location of the
targeted CRISPR cut site. The comparison of the percent methylation of the CpG sites observed at the localized CGI region for the CRISPR-edited
animal (Fig. 5c) and the unedited control animal (Fig. 5d) demonstrates the introduced methylation variance as a result of the adoption of the
donor DNA. Blue squares (■) indicate the percent differences in CpG methylation for HDR2 Animal from Control 2 Animal at given chromosome
locations. Red diamonds (♦) indicate the percent differences in CpG methylation for Control 1 Animal from Control 2 Animal at given
chromosome locations





Fig. 7 (See legend on next page.)
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For the CpG locations of the defined CGIs within the
study, our evaluations focused on CGIs with an in-
creased methylation profile at their CpG locations as
compared to control animals, requiring a minimum of
five bisulfite sequence calls at each CpG location for in-
creased confidence in the downstream statistical assess-
ments for determining and evaluating the edited CGIs.
While observations were made requiring a minimum as
low as two and as high as twenty bisulfite sequence calls
at each CpG location, no loss of information was ob-
served by increasing the minimum to as high as ten
calls.
In the ranking of significantly changed CGIs as com-
pared to those of the control animal across the genome
(Tables 3, 4, 5, and 6), corrected significance levels (α*)
for hypothesis testing using the Bonferroni method in-
creased the stringency of each individual CGI test and
the resulting significant p-values were ranked by the
smallest value indicating the CGI with the most signifi-
cant change. Further, a greater than 20% methylation in-
crease for more than 50% of the observed CpG locations
within each CGI was required to account for observed
biological variance. The increase of methylation within
the top ranked CGIs as indicated by the p-values
highlighted both of the HDR modified CGIs as contain-
ing the most significantly changed methylation profiles
for their respective comparisons, targeting CGI candi-
dates for deeper observation of the methylation patterns
displayed within them. In contrast, the NHEJ modified
CGI of the NHEJ1 Animal did not display a significant
change in methylation pattern compared to the control
animal and was not observed in the top ranking chan-
ging CGIs, reflecting the lack of integration of donor
DNA within the genomic sequence of the edited CGI.
The dynamic nature of methylation changes within
CGIs to control gene expression levels in response to
stimuli such as environmental and developmental vari-
ables results in natural fluctuations of CGI methylation
profiles. Comparison of genomic CGI methylation pro-
files of two control animals within this study (Table 6)
indicated a significantly modified CGI with a p-value re-
sembling that of the partially edited CGI (Table 4) and
methylation distribution counts resembling that of the
completely edited CGI (Table 3). These findings
emphasize that ranking of changed CGIs using the
methodology described in this study for the purposes of
(See figure on previous page.)
Fig. 7 Methylomic variance of a CpG island within the genome of the NHEJ1 Animal flanking a non-homologous end-joining repair in a CRISPR-
mediated edit. A non-homologous end-joining repair of a CRISPR-mediated genomic cut flanking a CpG island (CGI; Chr6:113,076,186–113,077,861;
yellow bar) was inserted within the genome of the NHEJ1 Animal, resulting in a methylation pattern of the edited animal (blue squares) that was
similar to that of the Control 1 Animal at the same location (red diamonds) localized around the CGI edit site (Fig. 6a) as well as 7000 bp upstream and
downstream of the edit (Fig. 6b). The gray band indicates considered biological epigenetic variance (+/− 20% change). The dashed line indicates the
protospacer adjacent motif (PAM) location of the targeted CRISPR cut site. The comparison of the percent methylation of the CpG sites observed at
the localized CGI region for the CRISPR-edited animal (Fig. 5c) and the unedited control animal (Fig. 5d) demonstrates a lack of variance in methylation
pattern as a result of non-homologous end-joining insertion of the 48-bp duplex DNA oligo fragment. Blue squares (■) indicate the percent
differences in CpG methylation for NHEJ1 Animal from Control 2 Animal at given chromosome locations. Red diamonds (♦) indicate the percent
differences in CpG methylation for Control 1 Animal from Control 2 Animal at given chromosome locations
Table 3 Case 1 p-value rankings for HDR1 Animal compared to Control 1 Animal
Degree of Experimental Methylation Level
Higher Than Control




p-value CpG Count 1–20%
Proportion
1–20% 21–40% 41–60% 61–80% 81–100%
15 11,035,894 11,038,084 3.852E-48 91 0.034 3 9 26 45 6
5 141,975,051 141,975,377 6.732E-12 23 0.043 1 10 10 2 0
15 89,523,499 89,524,359 1.555E-09 62 0.388 19 21 8 1 0
1 126,092,971 126,093,200 2.973E-09 16 0.125 2 5 8 1 0
7 45,098,344 45,098,676 2.978E-09 15 0.000 0 0 4 7 3
10 128,262,409 128,262,692 2.055E-08 12 0.083 1 10 1 0 0
8 116,827,244 116,827,574 2.268E-08 13 0.077 1 1 9 2 0
4 22,057,643 22,057,924 6.841E-08 11 0.000 0 10 1 0 0
15 38,118,394 38,118,655 7.345E-08 16 0.250 4 11 1 0 0
19 38,914,796 38,915,109 9.360E-08 12 0.083 1 7 4 0 0
The p-value represents the upper-tail p-value for the hypothesis test of higher methylation in the experimental mouse than the control mouse. The CG count
includes the total number of CGs in the CpG island. The proportion and category counts only refer to the number of CGs where the experimental CG methylation
level is higher than the control CG methylation level
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Table 4 Case 1 p-value rankings for HDR2 Animal compared to Control 1 Animal
Degree of Experimental Methylation Level
Higher Than Control




p-value CpG Count 1–20%
Proportion
1–20% 21–40% 41–60% 61–80% 81–100%
6 113,076,186 113,077,861 5.384E-23 135 0.229 19 45 19 0 0
16 4,846,725 4,846,950 2.937E-10 12 0.000 0 1 10 1 0
1 126,092,971 126,093,200 3.224E-10 16 0.313 5 11 0 0 0
12 84,038,314 84,038,998 3.593E-10 37 0.406 13 14 5 0 0
6 3,200,773 3,201,615 8.468E-10 35 0.355 11 20 0 0 0
7 31,208,206 31,208,620 1.111E-08 24 0.455 10 11 1 0 0
3 101,982,373 101,982,595 4.617E-08 27 0.480 12 9 4 0 0
10 126,861,656 126,861,911 1.620E-07 15 0.200 3 7 5 0 0
2 34,639,014 34,639,339 2.409E-07 22 0.400 8 10 2 0 0
The p-value represents the upper-tail p-value for the hypothesis test of higher methylation in the experimental mouse than the control mouse. The CG count
includes the total number of CGs in the CpG island. The proportion and category counts only refer to the number of CGs where the experimental CG methylation
level is higher than the control CG methylation level
A B
C D
Fig. 8 Edited CGIs affected by HDR show statistically significant p-values. In evaluating the methylation variance between CRISPR-edited and
control mouse epigenomes, top CGIs for each comparison were determined by ranking of p-values observed and removing those CGIs that did
not display greater than 50% of observed CpGs with methylation increases above 20%. Those top CGIs containing HDR edits had more significant
p-values for methylation increase above biological variance (20% change) as compared to other CGIs across the mouse genome for HDR1 Animal
(a) and HDR2 Animal (b). A CGI with a complete modification of its methylome displayed a significant increase of p-value over the control (a),
while a CGI with only a partial modification displayed an increase of p-value over the control at a lesser significance (b). The top CGIs with
methylation change within NHEJ1 Animal containing a NHEJ edit had no significant increase of p-value above biological variance, and the edited
CGI was not among the top CGIs with methylation change (c). Comparison of CGIs in unedited Control 2 Animals displayed a low significance of
change for the top CGIs (d)
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indicating HDR modified CGIs in a de novo manner
would require additional validating indicators to defini-
tively assert that a given CGI had been purposefully
modified using a CRISPR-targeted HDR mechanism.
Our methodology filters the CGIs to a more manageable
number for further investigation. For example, instead of
individually looking at the methylation pattern of 71,120
CGIs, this approach reduced the number to nine CGIs
for further investigation using additional indicators. Such
additional indicators might include direct sequence
modifications (e.g., indels or nucleotide substitutions) or
unexpected changes in transcription levels for a gene
that might be under regulation by the affected CGI.
In the evaluation of the CRISPR-edited CGIs, the
methylome observation at CpG locations within the tar-
geted CGIs were bisulfite sequenced at levels above that
of the overall respective genome-wide CpG bisulfite se-
quences (Fig. 3). These observations increase the confi-
dence in the statistical evaluations for the CpGs of the
edited CGIs.
CRISPR-mediated genome modification using HDR
mechanisms to incorporate novel sequence into the gen-
ome of the mouse zygote resulted in observable and per-
sistent destabilization of the modified methylation
patterns of the CGIs affected by the donor DNA (Figs. 5
and 6). In both edits, a marked increase of methylation
is observed within the affected CGIs for the CpG loca-
tions spanning the range of genomic incorporation of
the donor DNA. The animals evaluated were at least 10
generations from the original founder animal showing
that these CpG nucleotide methylation changes persist
over generations as an echo or scar of the introduced
novel genomic edit. The same observable modification
in the CGI methylation pattern did not occur in the
CRISPR-mediated 48-base insertion leveraging the NHEJ
repair mechanisms (Fig. 7). In the mechanics of the edit,
the NHEJ edit did not replace the genomic sequence of
the CGI with donor DNA recombination template dur-
ing its application, leaving the endogenous methylation
pattern unmodified. The unmodified methylome
Table 6 Case 1 p-value rankings for Control 2 Animal compared to Control 1 Animal
Degree of Experimental Methylation Level
Higher Than Control




p-value CpG Count 1–20%
Proportion
1–20% 21–40% 41–60% 61–80% 81–100%
11 6,006,144 6,007,748 4.011E-20 27 0.000 0 1 4 14 8
4 134,159,558 134,164,691 5.662E-13 28 0.179 5 14 7 2 0
8 85,129,693 85,132,058 2.147E-09 10 0.000 0 7 3 0 0
8 10,978,436 10,978,759 2.607E-09 12 0.167 2 10 0 0 0
15 93,908,948 93,909,153 8.615E-08 10 0.000 0 9 1 0 0
4 146,941,454 146,942,785 2.027E-07 79 0.321 18 25 13 0 0
5 147,029,103 147,029,460 2.538E-07 15 0.467 7 7 1 0 0
15 38,118,394 38,118,655 3.010E-07 10 0.000 0 9 1 0 0
5 129,918,271 129,918,590 3.579E-07 14 0.286 4 5 5 0 0
3 69,393,711 69,394,087 5.160E-07 13 0.231 3 10 0 0 0
The p-value represents the upper-tail p-value for the hypothesis test of higher methylation in the experimental mouse than the control mouse. The CG count
includes the total number of CGs in the CpG island. The proportion and category counts only refer to the number of CGs where the experimental CG methylation
level is higher than the control CG methylation level
Table 5 Case 1 p-value rankings for NHEJ1 Animal compared to Control 1 Animal
Degree of Experimental Methylation Level
Higher Than Control




p-value CpG Count 1–20%
Proportion
1–20% 21–40% 41–60% 61–80% 81–100%
2 153,071,685 153,072,285 1.222E-08 53 0.455 20 18 6 0 0
5 133,842,301 133,842,658 3.997E-07 9 0.000 0 6 3 0 0
7 96,797,289 96,797,521 6.555E-07 10 0.300 3 7 0 0 0
15 38,118,394 38,118,655 7.027E-07 9 0.000 0 5 4 0 0
3 71,974,851 71,975,406 8.074E-07 6 0.000 0 6 0 0 0
The p-value represents the upper-tail p-value for the hypothesis test of higher methylation in the experimental mouse than the control mouse. The CG count
includes the total number of CGs in the CpG island. The proportion and category counts only refer to the number of CGs where the experimental CG methylation
level is higher than the control CG methylation level
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observed in the NHEJ-edited CGI indicates that this type
detection method would not detect an edit facilitated by
NHEJ as being introduced using CRISPR technology.
Other genomic scaring indicators would be necessary to
specify the blunt-end repair editing method. In this
study, the integrated fragments in the mice modified by
HDR are larger (11 kb and 2005 bp) than the integrated
fragment in the mouse strain modified by NHEJ (48 bp).
Takahashi, et al. [38], reported in 2017 that the inte-
gration of CpG-free DNA into CGI regions of human
pluripotent stem cells induced de novo methylation of
the modified CGIs. The observed de novo methylation
had an absolute requirement for the integrated DNA to
be free of CpGs with DNA fragments containing CpGs
resulting in no change in methylation. In contrast, the
CGI methylation observed in Fig. 5 and Fig. 6 are not
the result of CpG-free DNA integration and map closely
to the homology arms of the donor DNA. As in the
study by Takahashi, et al., the findings described here
point similarly to the potential introduction of epimuta-
tions into the genome during the implementation of
CRISPR genome modifications.
Detecting or directing the modification of the
methylome using CRISPR technology has implications
in mitigating disease states, controlling gene expres-
sion, and determining when genetic modifications
have been introduced into the genome. It has been
reported that using CRISPR to modify the methylome
patterns of the cell has impact on cellular function
[33, 39]. The methylation of CpG locations within the
genome is one mechanism for controlling the degree
of gene expression at the cellular level, providing
variable and tunable gene expression profiles across
different tissue types [40, 41]. This control of gene
expression allows for the genome to conduct tissue-
specific functions and to respond to environmental
influences [41, 42]. Disruptions of these methylation
patterns within specific regions of the genome have
been associated with disease states such as cancer and
neurological disorders [43]. For example, in the case
of imprinting, methylation of a given allele of a gene
from either the maternal or paternal strand can si-
lence the given allele for the lifetime of the cell [44].
The human diseases of Angelman syndrome, Prader-
Willi syndrome, Beckwith-Wiedemann syndrome, and
certain cancers are affected by paternal imprinting
[45]. In these cases, the parentally inherited shutdown
of a gene may allow expression of a defective gene or
result in the silencing of both gene copies through
uniparental disomy, resulting in disease [45]. Applica-
tion of CRISPR technology to modify the epigenetic
imprint of an entire gene or its promoter region may
provide a technique for rescuing these type genetic
disease states [33, 46]. In similar application,
Alexander, et al., recently reported the silencing of
the HPRT1 housekeeping gene for cellular purine re-
cycling by replacing a CpG island with in vitro meth-
ylated alleles of the CGI using dual cut NHEJ editing
[33]. From their results, they concluded that the
methylation of elements in the promoter region of a
gene can functionally silence the expression of the
gene.
The expansion of technical methodologies and the
opening of application spaces for CRISPR genome edit-
ing facilitates advancements in synthetic biology and
pathways to basic discoveries and new clinical therapies.
In parallel, the potential costs of introducing disease
states, environmentally toxic influences, and other con-
cerning biological alterations of consequence call for
CRISPR detection mechanisms that follow the technical
progression of CRISPR modalities. The potential effects
of inadvertently or intentionally inserting a genomic edit
into a genome for directed modification purposes im-
plies the need for the parallel development of equally di-
verse sets of methods for detection of these edits. The
methodology described here represents one approach to
detecting genomic scars left behind during the applica-
tion of CRISPR, and we would suggest similar observa-
tions for other genomic modification approaches.
Conclusions
In this study, we demonstrate that using CRISPR editing
for the insertion of donor DNA using HDR modifies the
epigenetic profile of the targeted region, increasing the
degree of methylation observed at local CGIs, replaced
with donor DNA. Further, these edits and the methyla-
tion changes persist over generations within the progeny
of edited individuals. In this way, making genome edits
with CRISPR technology at regions of importance to
regulation of transcriptional gene expression may modify
the epigenetic profile of genes and their regulators of ex-
pression, affecting the expression profile of the gene or
genes in the vicinity. In developing strategies for gen-
omic modifications, consideration should be given to the
induced modification of the epigenetic profile that can
display inheritable persistence across generations. These
types of applied CRISPR-mediated epigenome edits may
represent a means to correct epigenetic disease variants
like genomic imprinting diseases. Further, the modifica-
tion of the methylome pattern represents a genomic scar
caused by the application of a directed CRISPR cut and
subsequent incorporation of donor DNA into the gen-
ome. While additional corroborating information is
needed to confirm these effects, our methodology high-
lights a supporting piece of evidence to indicate the
introduction of a CRISPR-mediated genome modifica-
tion using homology-directed repair.
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Methods
Animal strains
Frozen mouse spleen tissue samples were provided by
Dr. Michael V. Wiles of The Jackson Laboratory, Bar
Harbor, ME, USA. The epigenomes of four CRISPR-me-
diated insertion strains and two genetically matched
control strains were evaluated using bisulfite sequencing
methods. Unedited control mouse strains C57BL/6 J
(JAX Stock Number 000664) as Control 1 and C57BL/
6NJ (JAX Stock Number 005304) as Control 2 were
used. Genetically-modified strains used for this study are
described in Table 1, abbreviated here as HDR1, HDR2,
and NHEJ1. Mice were group housed in a climate-
controlled facility with a 12-h light/dark cycle and free
access to food and water. This study was conducted in
accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals [47]. All animal
protocols were reviewed and approved by The Jackson
Laboratory Animal Care and Use Committee (Summary
#11006). Animals were euthanized by cervical disloca-
tion and all efforts were made to minimize suffering.
Tissue processing
For replicate animals for each strain, genomic DNA
(gDNA) was extracted from excised spleen tissues of the
respective strains and processed for overall genomic
methylation patterns. For each animal, 5 mg of spleen
tissue were ground by mechanical disruption using li-
quid nitrogen grinding. gDNA was isolated using a
modified protocol of the Genomic DNA Isolation Kit
(AbCam; #ab65358). Using 35 μL of cell lysis buffer, the
pulverized tissue was washed by centrifugation. The
supernatant containing cellular debris was discarded,
and the resulting pellet of isolated nuclei was suspended
in 40 μL of cell lysis buffer. Kit enzyme mix (5 μL) was
added to the solution, mixed by gentle pipetting, and in-
cubated in a 55 °C water bath for 1 h. gDNA was isolated
from the extraction mixture using a modified protocol
of the paramagnetic bead DNA isolation in the ChargeS-
witch gDNA Micro Tissue Kit (Thermo Fisher Scientific;
#CS11203). 1 ml ChargeSwitch Lysis Buffer (L15) and
10 μL of proteinase K were added to the nuclei lysate.
The mixture was incubated in a 55 °C water bath for 1 h.
After incubation, 5 μL of RNase A was added to the lys-
ate and homogenized by pipetting. The mixture was in-
cubated at room temperature for 5 min. gDNA was
isolated following the DNA binding, DNA washing, and
DNA elution processes described by the manufacturer
protocol. The elution volume was concentrated using a
Savant DNA120 SpeedVac Concentrator (Thermo Fisher
Scientific) to a volume of 100 μL. The concentration of
recovered gDNA for each sample was measured using
the Qubit 3.0 fluorometer system (Thermo Fisher Scien-
tific). Quality of each sample was evaluated using a DNA
12000 Chip Kit (Agilent; #5067–1508) on a 2100 Bioana-
lyzer System (Agilent; #G2939BA).
Bisulfite conversion and sequencing was performed by
Zymo Research, using a Methyl MaxiSeq service. Briefly,
methyl-seq libraries were prepared using 500 ng of gen-
omic DNA, fragmented with 2 units of dsDNA Shearase
Plus (Zymo Research; #E2018–50). The resulting gen-
omic fragments were end-blunted and the 3′ terminus
was modified with an adenine extension. The fragments
were subsequently purified using the DNA Clean &
Concentrator-5 kit (Zymo Research; #D4003). A-tailed
genomic fragments were ligated to pre-annealed
adapters containing 5′-methylcytosine in place of cyto-
sine. Adapter-ligated fragments were repaired to
complete duplex strands. Bisulfite conversion of the
fragments was performed using the EZ DNA Methyla-
tion—Lightning kit (Zymo Research; #D5030). The frag-
ments were amplified by polymerase chain reaction
using adapter targeted primers with Illumina TruSeq in-
dices. The size and concentration of the fragments were
confirmed using an Agilent 2200 TapeStation. Methy-
lome fragments were sequenced on an Illumina HiSeq
instrument, generating paired-end 150-bp read lengths.
The whole genome bisulfite sequencing technique was
used to provide a genome-wide overview of CpG methy-
lation patterns for interactions of Cas9 across the gen-
ome and observations of the modified methylation
patterns of the edit site.
Bioinformatic processing of methylome sequences
Both 5-methylcytosine and 5-hydroxymethylcytosine are
detected by bisulfite treatment; however, the ratios be-
tween the two are not distinguished [48]. DNA methyla-
tion within this study was defined as a combination of
both genomic methylation variants. Computational post-
processing of methylome DNA sequence reads produced
through bisulfite sequencing were organized and binned
into paired, sample-specific files according to multiplex
identifier (MID) sequences. The paired files were evalu-
ated for sequence quality using Trimmomatic [49] in
paired-end mode. Low quality sequences, sequencing ar-
tifacts, sequencing adapters, and MIDs were removed
from the binned reads. The settings within the Trimmo-
matic program set a seed mismatch tolerance of 2, a pal-
indrome clip threshold of 30, a simple clip threshold of
15 bp, minimal adapter length of 8 bp, Phred values set
to a minimum of 10 for leading and trailing bases, a slid-
ing window length of a minimum of 4 bp with a mini-
mum Phred score of 15, and a minimum length of a
given read set to 36 bp.
Quality-trimmed reads for each sample were aligned,
respectively, in a paired-end sequence alignment to the
mouse reference genome (version GRCm38.p6) using
the BWA-Meth aligner [50]. The resulting sequence/
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alignment map (SAM) files were sorted using SAMtools
sort of the SAMtools suite version 1.7 [51], converting
the SAM files to sorted binary sequence/alignment map
(BAM) files. Optical and library duplicates were identi-
fied and removed using Picard MarkDuplicates [52]. The
deduplicated BAM files were indexed using SAMtools
index [51], and depth of coverage at each region was cal-
culated using SAMtools depth [51]. Genome-wide CpG
methylation calls and evaluations were performed using
MethylDackel [53]. The resulting BedGraph files were
visualized using the Integrative Genomics Viewer ver-
sion 2.5.2 (IGV; Broad Institute, Cambridge, MA) [54]
and parsed for statistical analysis with Python version
3.8.0 [55] scripting. For each CpG dinucleotide, the esti-
mated methylation level was obtained after merging
methylated and unmethylated read counts for the cyto-
sines. For use in statistical evaluations, the read depth
for the cytosine of each CpG dinucleotide location was
required to be a minimum of five.
With a Python script, CpG islands (CGIs) were defined
and called within the mouse genome as previously out-
lined by Gardiner-Garden and Frommer [18]. The pre-
scribed definition characterized islands greater than or
equal to 200 base pairs in length with a G/C content
greater than 50% and an observed to expected CpG ratio
(O/E) greater than 0.6, where
O=E ¼ #CpG=N
#C=N  #G=N
The identified CGI genomic locations were used to fil-
ter the MethylDackel methylation calls, focusing only on
CpGs located within the CGI ranges. To consolidate re-
gions with enriched CpG content, a Python script
stitched together genomic regions with CGI ranges lo-
cated within 100 base pairs of each other.
Statistical methods
Statistical analyses were leveraged to define a path to the
location of a CRISPR-edited genomic site. At CGIs of
the edit location, the methylation level of the experimen-
tal animal was assumed to be higher than that of the
control animal due to cellular maintenance of CGIs in
unmethylated states. A two-step evaluation approach
was adopted to determine significant differences in in-
creased methylation levels between the CRISPR-edited
and control animals.
The first step evaluates the methylome data for
genome-wide CGIs in a statistical hypothesis test of
methylation level differences between the CGIs of the
experimental and control animals. Since the experimen-
tal animal is anticipated to have higher methylation
levels at the CRISPR edit site, an upper-tail, paired t-test
with a significance level (α) of 0.05 was used.
The resulting hypothesis test for each CGI is:
Ho: μ of genetically-edited animal methylation level ≤ μ
of control animal methylation level
Ha: μ of genetically-edited animal methylation level > μ
of control animal methylation level
or
Ho: μd ≤ 0
Ha: μd > 0
Where μd is the mean methylation level difference of
the genetically-edited animal methylation level from the
control animal methylation level at each CpG site within





xi experimental ¼ experimental methylation at CpGi
yi control ¼ control methylation at CpGi






  ¼ sdffiffiffi
n
p
The t statistic follows a t distribution with n-1 degrees
of freedom.
The total number of CGIs for each genetically-edited
animal tested against Control 1 animal are shown in
Table 2, indicating the number of p-value test that were
conducted for each comparison. Therefore, in order to
keep the overall test between animals at the 5% level of
significance, the following Bonferroni correction factor
was utilized, where α* equals:
α ¼ α
Number of CGIs
A second filter was then applied to the paired t-test re-
sults to filter biological epigenetic noise inherent to the
epigenetic buffering of the transcriptome [56]. In apply-
ing this filter, CpGs within the CGI ranges were consid-
ered only where the genetically-edited animal CpG
methylation was greater than the CpG methylation of
the control animal. The remaining positive CpG methy-
lation differences, resulting from the subtraction of the
qualifying CpG methylation percentage of Control 1
Animal from those of CRISPR-edited animals or the
Control 2 Animal, were then binned into the following
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categories, respective to the evaluations: ≤20%, 21–40%,
41–60%, 61–80%, and 81–100%.
If the level of increase in the genetically-edited animal
at the given CpG location was less than or equal to 20%,
it was considered to be biological epigenetic noise as ob-
served across other CGIs within the genomes and not
considered a significant epigenetic change. For the filter,
the proportion of differences that were less than or equal
to 20% was set at 0.5 across the given CGI range. This
resulted in four specific categorical cases. Case 1 con-
tains significantly increased methylation levels for the
genetically-edited animal and a small degree of epigen-
etic noise (> 50% of CpGs with > 20% increase in methy-
lation). Case 2 also contains significantly increased
methylation levels for the genetically-edited animal but
has a larger degree of epigenetic noise (< 50% of CpGs
with > 20% increase in methylation). Neither Case 3 nor
Case 4 contains significantly increased methylation levels
for the genetically-edited animal; Case 3 has a small de-
gree of epigenetic noise (> 50% of CpGs with > 20% in-
crease in methylation) whereas Case 4 has a larger
degree of epigenetic noise (< 50% of CpGs with > 20%
increase in methylation).
Visualizing methylation calls and variance
Initial variance at the known genomic edit sites were ob-
served in comparisons of the sequenced methylomes of
edited animals and control animals at their respective
edit locations using IGV [54]. Methylation profiles from
the genomic regions of the animals within the alignment
BedGraph files generated by analysis in MethylDackel
were mapped to the Mus musculus (house mouse) refer-
ence genome version GRCm38 (mm10).
With a Python script, the percent of CpG call depths
were calculated for each CpG within CGIs across the
genome for each animal and for CRISPR-edited CGIs for
HDR1 Animal, HDR2 Animal, and NHEJ1 Animal. The
percent of CpG at given call depths (1 to 10 and greater
than 10) were read into a Python 3 Pandas DataFrame
(version 0.25.1) [57]. The DataFrame was used as input
to the Python 3 Matplotlib version 3.1.1 module pyplot
[58] to generate bar plots comparing these calculated
genome-wide sequence depths of CpG locations for each
animal.
To relate the depth of the bisulfite sequencing cover-
age at each CRISPR-edited CGI to the coverage observed
across all other CGIs within its respective genome, the
variance observed between the methylomes of CRISPR-
edited CGIs and unmodified CGIs at their CpG locations
were plotted in overlaid bar plots using Pandas Data-
Frames and Matplotlib module pyplot. Qualifying CpGs
eligible for evaluation at the CGI sites contained five
calls or more at the cytidine residue. In each plot, the
difference in the degree of methylation observed within
the experimental animal (HDR1 Animal, HDR2 Animal,
or NHEJ1 Animal) and Control 2 Animal were measured
against the observed methylome of Control 1 Animal.
Qualifying methylation calls were pulled from observa-
tions in BedGraph files from MethylDackel evaluations
for the corresponding animals. Documented from the
mouse reference genome, CpG locations within the
mouse genome were recorded as a baseline for compari-
son against the experimental animals. For each given
edited CGI, the chromosome, the CGI start location co-
ordinate, and the CGI end location coordinate were de-
fined to bound the data and resulting plot to the CRIS
PR-targeted CGI genomic location for the comparisons.
The bounded data for each animal consisted of a gen-
omic start location coordinate, a genomic end location
coordinate, and observed percent methylation at the lo-
cation for qualifying CpG locations within the bounded
CGI genomic range. In each comparison and at each
qualifying CpG location, the percent methylation values
observed for the Control 1 Animal were subtracted from
the qualifying CpG locations of the CRISPR-edited ani-
mal and the Control 2 Animal. Visual representations of
the measured CpG methylation differences for the CRIS
PR-targeted CGI were illustrated using difference plots
for each qualifying CpG location of each edited and con-
trol animal as compared to Control 1. Difference plots
were generated as compound scatter plots using the
Matplotlib module pyplot.
Manhattan plots were used to illustrate the degree of
p-value variance observed among CGIs identified as
appearing within their respective Case 1 classification
and containing statistically changed methylation profiles.
The calculated p-values for each Case 1 classified CGI
within each respective comparison (HDR1 Animal to
Control 1 Animal, HDR2 Animal to Control 1 Animal,
NHEJ1 Animal to Control 1 Animal, and Control 2 Ani-
mal to Control 1 Animal) along with the chromosome
and CGI start location coordinates were organized ac-
cording to chromosome and location order in Pandas
DataFrames. Using the Matplotlib module pyplot, the
-log10 calculations of the p-values were illustrated as a
scatter plot arranged by chromosome and location order
for each comparison.
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Additional file 1: Supplemental Table 1. CGI algorithm statistics
across the mouse genome. The CGI defining and stitching algorithm was
developed and used to call CpG-rich ranges within the mouse genome.
Results of the analysis provided a basis for determining targeted ranges
for evaluating clustered CpG methylation variance across genomes.
Additional file 2: Supplemental Fig. 1. The top Case 1 CGIs identified
for the NHEJ1 Animal using the statistical workflow did not correspond
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to the edited CGI location (Table 5). Difference profiles of the NHEJ1
Animal compared to Control 1 Animal of the two most significantly
changed CGIs—Chr2:153,071,685-153,072,285 (A) and Chr5:133,842,301-
133,842,658 (B)—demonstrate non-uniform methylation fluxuation in
Chr2 and a change in both the Control and NHEJ1 in Chr5. In contrast,
the HDR edits of Figs. 5 and 6 display uniform increase in methylation in
the CpGs of the CGI above that of the Control. Blue squares (■) indicate
the percent differences in CpG methylation for NHEJ1 Animal from Con-
trol 2 Animal at given chromosome locations. Red diamonds (♦) indicate
the percent differences in CpG methylation for Control 1 Animal from
Control 2 Animal at given chromosome locations.
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